Valsartan
From Wikipedia, the free encyclopedia
| Image:Valsartan.svg | |
| Valsartan
| |
| Systematic (IUPAC) name | |
| 3-methyl-2- [pentanoyl-[ [4-[2-(2H-tetrazol-5-yl) phenyl] phenyl] methyl]amino] -butanoic acid | |
| Identifiers | |
| CAS number | 137862-53-4 |
| ATC code | C09CA03 |
| PubChem | 60846 |
| DrugBank | APRD00133 |
| Chemical data | |
| Formula | C24H29N5O3 |
| Mol. weight | 435.519 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 95% |
| Metabolism | ? |
| Half life | 6 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
D |
| Legal status |
℞ Prescription only |
| Routes | oral |
Valsartan (trade name Diovan®) is an angiotensin II receptor antagonist, acting on the AT1 subtype. In the U.S., valsartan is indicated for treatment of high blood pressure, of congestive heart failure (CHF), and post-myocardial infarction (MI). In 2005, Diovan® was prescribed more than 12 million times in the United States.
[edit] Administration
Oral tablets, containing 40 mg (scored), 80 mg, 160 mg or 320 mg of valsartan. Usual dosage ranges from 40–320 mg daily.
Diovan HCT® contains a combination of valsartan and hydrochlorothiazide but, unlike Diovan®, is only indicated for hypertension, not for CHF or post-MI.
[edit] Side effects
Most commonly, headache and dizziness.
[edit] External links
| Angiotensin II receptor antagonists (AIIRA) (C09C) edit | ||
|---|---|---|
|
Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Tasosartan, Telmisartan, Valsartan | ||
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
